Boston Scientific Corporation $BSX Holdings Lowered by Strengthening Families & Communities LLC

Strengthening Families & Communities LLC trimmed its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 43.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 830 shares of the medical equipment provider’s stock after selling 636 shares during the quarter. Strengthening Families & Communities LLC’s holdings in Boston Scientific were worth $84,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in BSX. Vanguard Group Inc. raised its holdings in shares of Boston Scientific by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider’s stock worth $13,577,311,000 after purchasing an additional 1,697,945 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Boston Scientific by 18.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,610,487 shares of the medical equipment provider’s stock worth $1,070,387,000 after purchasing an additional 1,664,108 shares in the last quarter. Swedbank AB raised its holdings in shares of Boston Scientific by 114.5% in the 2nd quarter. Swedbank AB now owns 2,819,249 shares of the medical equipment provider’s stock worth $302,816,000 after purchasing an additional 1,505,019 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Boston Scientific by 10.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 14,143,332 shares of the medical equipment provider’s stock worth $1,426,779,000 after purchasing an additional 1,383,524 shares in the last quarter. Finally, Ninety One UK Ltd raised its holdings in shares of Boston Scientific by 33.5% in the 2nd quarter. Ninety One UK Ltd now owns 5,146,218 shares of the medical equipment provider’s stock worth $552,755,000 after purchasing an additional 1,290,414 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Stock Performance

Shares of BSX opened at $95.41 on Friday. The company’s 50 day moving average price is $101.98 and its 200 day moving average price is $101.87. Boston Scientific Corporation has a 52 week low of $80.64 and a 52 week high of $109.50. The company has a market capitalization of $141.38 billion, a PE ratio of 56.79, a PEG ratio of 2.34 and a beta of 0.61. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The firm had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. During the same period in the previous year, the firm posted $0.62 earnings per share. The firm’s revenue was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Research analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Analyst Ratings Changes

BSX has been the topic of a number of research reports. Wall Street Zen upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating in a report on Saturday. Leerink Partners boosted their price target on shares of Boston Scientific from $127.00 to $128.00 and gave the company an “outperform” rating in a report on Wednesday, October 1st. Weiss Ratings restated a “buy (b-)” rating on shares of Boston Scientific in a report on Wednesday. Jefferies Financial Group restated a “hold” rating on shares of Boston Scientific in a report on Monday, July 21st. Finally, Canaccord Genuity Group boosted their price target on shares of Boston Scientific from $131.00 to $132.00 and gave the company a “buy” rating in a report on Wednesday, October 1st. Two analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, Boston Scientific presently has a consensus rating of “Buy” and an average price target of $120.71.

Insider Activity at Boston Scientific

In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business’s stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $5,231,500.00. Following the completion of the sale, the executive vice president directly owned 178,342 shares of the company’s stock, valued at $18,659,923.46. The trade was a 21.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Edward J. Ludwig sold 4,000 shares of the business’s stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $106.03, for a total transaction of $424,120.00. Following the completion of the sale, the director directly owned 18,479 shares of the company’s stock, valued at $1,959,328.37. This represents a 17.79% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 174,214 shares of company stock valued at $17,972,457. Company insiders own 0.50% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.